Showing results (1-10 of 328) with videos related to
Sort By:
Pageof 33
Interventional Cardiology Clinics|June 6, 2017
Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial InfarctionRafael Harari, Usman BaberNature Reviews. Nephrology|March 14, 2012
Prevention of contrast-induced AKI--the ongoing sagaUsman Baber, Roxana MehranCurrent Opinion in Cardiology|May 3, 2017
Antiplatelet treatments: recent evidence from randomized controlled trialsBirgit Vogel, Usman BaberCurrent Cardiology Reports|July 12, 2013
Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndromeUsman Baber, Uschi AugusteCurrent Opinion in Cardiology|May 15, 2019
Clinical trials in long-term antiplatelet therapies: focus on the role of aspirinRidhima Goel, Usman BaberThe Medical Clinics of North America|March 28, 2024
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?Khawaja Hassan Akhtar, Usman BaberInterventional Cardiology Clinics|September 14, 2020
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial ExperienceZain Ul Abideen Asad, Usman BaberUS Cardiology|December 25, 2024
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary InterventionJohny Nicolas, Usman Baber, Roxana MehranInterventional Cardiology Clinics|June 6, 2017
Future Perspectives on Percutaneous Coronary Interventions in WomenJennifer Conroy, Usman Baber, Roxana MehranCurrent Opinion in Cardiology|May 21, 2014
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?Georgios Christodoulidis, Usman Baber, Roxana MehranPageof 33